Edwyn
Over the five-year period, Merck’s revenue and gross profit have generally trended upward. Revenue climbed from USD 47,994 million in 2020 to USD 64,168 million in 2024. Notably, 2022 experienced a significant jump of approximately 22% over the prior year, suggesting a period of accelerated growth. Gross profit displayed a similar upward trajectory, increasing from USD 32,509 million in 2020 to USD 48,975 million in 2024. The data shows marked year-over-year variations—most prominently in 2022, where gross profit rose by about 19% compared to 2021, followed by a more modest increase in 2023 and a subsequent rebound in 2024. Despite these robust revenue and gross profit figures, the operating income remains recorded as zero throughout, which might indicate either a reporting anomaly or missing data for this metric. Net income, however, has been more volatile. It nearly doubled from USD 7,067 million in 2020 to USD 13,049 million in 2021, then continued a modest increase to USD 14,519 million in 2022. A significant anomaly occurs in 2023, when net income plummets to just USD 365 million—a drop of over 97% from the previous year—before rebounding strongly to USD 17,117 million in 2024, an increase of over 1,600% year-over-year. This sharp fluctuation may be attributable to one-off events or extraordinary items affecting the net income figure, but the underlying revenue and gross profit growth suggest solid operational performance. Overall, based on the provided metrics, Merck appears financially robust with steadily increasing top-line and gross profitability, although the net income volatility in 2023 highlights the importance of understanding non-operational influences on profitability.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.